NICE Issues Guidance On Treatments For Hepatitis B
Main Category: Liver Disease / HepatitisArticle Date: 28 Aug 2008 - 4:00 PDT
| Patient / Public: | ![]() |
4 (2 votes) |
| Healthcare Prof: | ![]() |
The National Institute for Health and Clinical Excellence (NICE) has published final guidance on the use of Entecavir and Telbivudine for the treatment of chronic hepatitis B.
NICE produced these two pieces of guidance as part of its rapid single technology appraisal (STA) work programme. The guidance states:
- Entecavir is recommended as an option for the treatment of people with chronic HBeAg-positive or HBeAg-negative hepatitis B in whom antiviral treatment is indicated.
- Telbivudine is not recommended for the treatment of chronic hepatitis B. People currently receiving telbivudine should have the option to continue therapy until they and their clinicians consider it appropriate to stop.
This guidance does not apply to people with chronic hepatitis B who also have hepatitis C, hepatitis D or HIV.
Dr Gillian Leng, NICE Deputy Chief Executive and Executive Lead for the guideline, said: "Hepatitis B is a disease that can have a serious impact on a person's quality of life, and those with the disease are more likely to develop serious liver problems such as cirrhosis and cancer. The independent Committee carefully considered the evidence and concluded that entecavir offered a good use of NHS resources for this condition."
About the guidance
1. The Entecavir and Telbivudine guidance is available at: http://www.nice.org.uk/TA153 and http://www.nice.org.uk/TA154 respectively.
About NICE
The National Institute for Health and Clinical Excellence (NICE) is the independent organisation responsible for providing national guidance on the promotion of good health and the prevention and treatment of ill health.
NICE produces guidance in three areas of health:
- public health - guidance on the promotion of good health and the prevention of ill health for those working in the NHS, local authorities and the wider public and voluntary sector
- health technologies - guidance on the use of new and existing medicines, treatments and procedures within the NHS
- clinical practice - guidance on the appropriate treatment and care of people with specific diseases and conditions within the NHS.
http://www.nice.org.uk
Visit our liver disease / hepatitis section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/119493.php>
APA
http://www.medicalnewstoday.com/releases/119493.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




